News

Find News

Filter articles

Applied Filters

Showing 1011 to 1020 of 1058 results

Teva holds on to Azilect exclusivity

US25-09-2013

The US District Court for the District of New Jersey has found in favour of Teva Pharmaceutical Industries Ltd in its patent infringement case with Mylan over Parkinson’s disease drug Azilect.

Ranbaxy receives notice for acne drug generic

US24-09-2013

Drug company Watson Laboratories (Actavis) has notified rival Ranbaxy Laboratories that it has applied to sell a generic version of anti-acne product Absorica in the US.

Austria becomes first country to ratify Unified Patent Court agreement

Austria, EU27-08-2013

Austria has become the first country in the EU to ratify consent to the Unified Patent Court.

Eli Lilly bids to stop generics cutting Alimta exclusivity

US23-08-2013

Eli Lilly has begun its defence of a patent covering lung cancer drug Alimta against generic companies including Teva, Barr Laboratories and APP Pharmaceuticals.

Horizon Pharma settles Duexis case with Par Pharmaceuticals

US22-08-2013Legal developments

US-based Horizon Pharma Inc agreed on August 22 to settle its patent dispute over arthritis drug Duexis with generic maker Par Pharmaceutical Companies.

IPAB revokes Allergan eye drug patent

India12-08-2013Legal developments

On August 8 the IPAB revoked another patent owned by a Western pharmaceutical company – this time related to Allergan’s eye drug Combigan.

IPAB throws out Indian Vega trademarks

India02-08-2013

The Intellectual Property Appellate Board in Chennai has cancelled two trademarks associated with versions of Viagra.

UK Appeals Court upholds Teva’s Copaxone patent

UK01-08-2013Legal developments

The Court of Appeal for England and Wales has upheld the Patent Court’s decision that Teva Pharmaceutical Industries’ UK patent 762,888, relating to the multiple sclerosis drug Copaxone, is valid.

FTC welcomes Supreme Court 'pay-for-delay' ruling

US25-07-2013

The chair of the FTC has said it will continue to challenge pay-for-delay court settlements in the pharmaceutical industry and has hailed a Supreme Court ruling as a victory for consumers.

Ability to settle cases influences generic patent challenges, study finds

US25-07-2013

A white paper suggests that patent case settlements between originator pharmaceutical companies and their generic competitors may be beneficial to drug consumers.

Showing 1011 to 1020 of 1058 results

LSIPR